Pirich C, Fitscha P, Schmid P, Sinzinger H
Department of Nuclear Medicine, University of Vienna, Austria.
Blood Press Suppl. 1994;1:70-4.
Experimental studies have demonstrated that isradipine significantly decreases the entry of radioiodine-labelled (125I) low-density lipoproteins (LDL) into the aorta. This study aimed to investigate whether similar effects could be detected in humans as well. Twelve patients (nine men and three women, aged from 35 to 53 years), all of whom had both hyperlipoproteinaemia (either type IIa or type IIb; mean total cholesterol: 296 +/- 25 mg/dl; mean LDL cholesterol: 208 +/- 22 mg/dl) and mild-to-moderate hypertension [mean systolic blood pressure (SBP): 149 +/- 12 mmHg; mean diastolic blood pressure (DBP): 104 +/- 4 mmHg] received isradipine (2 x 2.5 mg). Autologous radiolabelled (123I) LDL was reinjected and a gamma camera used to study the LDL kinetics before (at 20 min, 2 h and 20 h) and after (at the same time intervals) treatment with isradipine. Of interest were those arterial regions that are typically sites of atherosclerotic lesions (carotid artery, femoral artery). Results revealed three different types of LDL kinetics which were not altered by isradipine treatment. The quantitative LDL entry, however, was reduced by at least 4.7% with a maximum of 23.5% (p < 0.01). Only five vascular sites with type III kinetics were detected. These data suggest that isradipine may induce functional regression of atherosclerotic lesions.
实验研究表明，伊拉地平可显著减少放射性碘标记（125I）的低密度脂蛋白（LDL）进入主动脉。本研究旨在调查在人类中是否也能检测到类似效果。12例患者（9名男性和3名女性，年龄35至53岁），均患有高脂蛋白血症（IIa型或IIb型；平均总胆固醇：296±25mg/dl；平均LDL胆固醇：208±22mg/dl）和轻至中度高血压[平均收缩压（SBP）：149±12mmHg；平均舒张压（DBP）：104±4mmHg]，接受伊拉地平治疗（2×2.5mg）。重新注射自体放射性标记（123I）的LDL，并使用γ相机研究伊拉地平治疗前（20分钟、2小时和20小时）和治疗后（相同时间间隔）的LDL动力学。感兴趣的是那些通常为动脉粥样硬化病变部位的动脉区域（颈动脉、股动脉）。结果显示存在三种不同类型的LDL动力学，伊拉地平治疗未改变其类型。然而，LDL的定量进入量减少了至少4.7%，最大减少了23.5%（p<0.01）。仅检测到5个具有III型动力学的血管部位。这些数据表明，伊拉地平可能诱导动脉粥样硬化病变的功能消退。
